| 6.32 0.1 (1.61%) | 10-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.01  |
1-year : | 10.25 |
| Resists | First : | 7.71 |
Second : | 8.77 |
| Pivot price | 6.86 |
|||
| Supports | First : | 6 |
Second : | 4.99 |
| MAs | MA(5) : | 6.53 |
MA(20) : | 7.03 |
| MA(100) : | 8.03 |
MA(250) : | 8.13  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 7.3 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 13.67 | Low : | 5.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KYTX ] has closed above bottom band by 6.4%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.44 - 6.48 | 6.48 - 6.52 |
| Low: | 5.91 - 5.96 | 5.96 - 6 |
| Close: | 6.25 - 6.32 | 6.32 - 6.38 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Sat, 03 Oct 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Thu, 01 Oct 2026
Bank of America Corp DE Makes New Investment in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Thu, 24 Sep 2026
Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4 - TradingView
Thu, 24 Sep 2026
Among 12 people with stiff person syndrome who used walking aids, 67% no longer needed them after one dose. - Stock Titan
Thu, 13 Aug 2026
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 8,500 (K) |
| Shares Short P.Month | 7,850 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.6 % |
| Return on Equity (ttm) | -87.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -159 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -2.17 |
| PEG Ratio | 0 |
| Price to Book value | 2.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|